Cerebral Blood Flow and Metabolism in Normal Human Aging, Pathological Aging, and Senile Dementia

Dastur, Darab K.

doi:10.1038/jcbfm.1985.1

Cited by 123 publications

(51 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many reports have suggested a decline in CBF with advancing age after the age of 20 as well (Kety, 1956;Melamed et aI., 1980;Pantano et aI., 1984;Shirahata et aI., 1985). However, as recently reviewed by Dastur (1985), newer methods used on human subjects and exper imental animals have shown that no parameter of brain blood flow and metabolism is disturbed in nor mal aging except a small but significant fall in the brain's utilization of glucose. The above discrepan cies may be explained in part by different criteria employed in the selection of elderly normal subjects in previous studies (Dastur, 1985).…”

Section: Effect Of Age Sex and Atrophy On Rcbfmentioning

confidence: 99%

^99mTc-d,l-HMPAO and SPECT of the Brain in Normal Aging

Waldemar

Hasselbalch²,

Andersen³

et al. 1991

J Cereb Blood Flow Metab

129

View full text Add to dashboard Cite

Summary: Single photon emission computed tomography (SPECT) with 99mTc-d,l-hexamethylpropyleneamine ox ime (99mTc-d,I-HMPAO) was used to determine global and regional CBF in 53 healthy subjects aged 21-83 years. For the whole group, global CBF normalized to the cer ebellum was 86.4% ± 8.4 (SD). The contribution of age, sex, and atrophy to variations in global CBF was studied using stepwise mUltiple regression analysis. There was a significant negative correlation of global CBF with sub jective ratings of cortical atrophy, but not with ratings of ventricular size, Evans ratio, sex, or age. In a subgroup of 33 subjects, in whom volumetric measurements of atro phy were performed, cortical atrophy was the only sig nificant determinant for global CBF, accounting for 27% of its variance. Mean global CBF as measured with the Tomographic measurement of regional CBF (rCBF) in humans was made possible several years ago with the development of a brain-dedicated dy namic single photon emission computed tomogra phy (SPECT) system designed for inhalation or in jection of the diffusible tracer \33Xe (Stokely et ai., 1980). This technique offers easy, repetitive, and quantitative measurements with a spatial and tem poral resolution sufficient for studying cerebrovas cular disease.The recent development of tracers that are re tained in the brain for several hours and, if ideal, "trapped" in proportion to regional blood flow has

show abstract

Section: Effect Of Age Sex and Atrophy On Rcbfmentioning

confidence: 99%

^99mTc-d,l-HMPAO and SPECT of the Brain in Normal Aging

Waldemar

Hasselbalch²,

Andersen³

et al. 1991

J Cereb Blood Flow Metab

129

View full text Add to dashboard Cite

show abstract

“…There was significant depression in the mean cerebral blood flow and cerebral metabolic rate for glucose values in Alzheimer and multi-infarct patients using PET (Dastur 1985;Deutsch and Tweedy 1987). Regional cerebral glucose metabolism was acknowleged as an index of neuronal activity, and the cortical involvement of glucose metabolism was considered to be consistent with the major clinical features of Alzheimer's disease (Foster et al 1984).…”

Section: Discussionmentioning

confidence: 99%

Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography.

Nagasawa

Kogure

Kawashima

et al. 1990

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

T., ITOH, M. and HATAZAWA, J. Effects of Go-Dergocrine Mesylate (Hydergine®) in Multi-Infarct Dementia as Evaluated by Positron Emission Tomography. Tohoku J. Exp. Med., 1990, 162 (3), 225-233 Three female patients aged from 74 to 79 with multiinfarct dementia were studied using positron emission tomography (PET) to assess the effect of co-dergocrine mesylate (Hydergine®) on cerebral glucose metabolism. The cerebral glucose utilization (CMRGIc) of each patient was evaluated by PET scan using 2-deoxy-['8F]-2-fluoro-D-glucose (FDG). Following the first PET study, 0.04 mg/kg of co-dergocrine mesylate was injected intravenously with 250 ml saline solution, and then the second PET study was performed. The CMRGIc was determined from the images of the PET scan and the radioactivity of 18F in the plasma. After the administration of co-dergocrine mesylate, the value of CMRGIc increased significantly in the cerebral cortex (p <0.01 and p <0.05) and basal ganglia (p <0.05) compared with values before the administration, but no significant increase was found in the centrum semiovale. These results suggest that co-dergocrine mesylate stimulates glucose metabolism of neurons in the human brain.co-dergocrine mesylate ; cerebral glucose metabolism ; positron emission tmography ; dementia ; stroke The investigation of the human brain function has been advanced by measuring a wide variety of functional parameters in vivo on a regional basis in the brain with positron emission tomography (PET) including blood flow, metabolism, pharmacokinetics, tissue pH, and the distribution of chemotherapeutic agents (Phelps et al. 1982;Raichle 1983;Yamamoto et al. 1984). The advantage of this imaging method is that it is not only qualitative, but quantitative, and repeated evaluations are possible. Thus, this study is applicable not

show abstract

“…Alzheimer-type dementia and vascular dementia. Several researchers have suggested that dementia induced by multiple cerebral infarction may result primarily from reductions of cerebral blood flow (CBF) and glucose metabolism in humans [1][2][3] as CBF and glucose metabolism play primary roles in brain energy production, and a lack of energy production induces serious disturbances in brain function and metabolism.…”

Section: Introductionmentioning

confidence: 99%

Nefiracetam Improves the Impairment of Local Cerebral Blood Flow and Glucose Utilization after Chronic Focal Cerebral Ischemia in Rats

Jin

Watabe²,

Yamamoto³

2002

Pharmacology

View full text Add to dashboard Cite

In this study we investigated the effects of nefiracetam (DM-9384) on local cerebral blood flow (LCBF) and local cerebral glucose utilization (LCMR_glc) in the chronic phase after middle cerebral artery (MCA) occlusion in rats. Nefiracetam (10 mg/kg) was administered orally once a day for 2 weeks from day 15 after MCA occlusion. On day 28 after MCA occlusion, LCBF and LCMR_glc were measured by an autoradiographic image-processing method. In MCA-occluded rats, LCBF and LCMR_glc in the ischemic side of seven regions including the frontal cortex were significant decreased compared with those of the nonischemic side. Nefiracetam significantly improved the impairment of LCBF in the frontal cortex, parietal cortex, caudate putamen, ventral thalamus, amygdaloid nucleus and hippocampus. It also improved the decrease of LCMR_glc in the frontal cortex, ventral thalamus and hippocampus. These results suggested that nefiracetam has ameliorating effects on chronic disorders of LCBF and LCMR_glc induced by MCA occlusion.

show abstract

Cerebral Blood Flow and Metabolism in Normal Human Aging, Pathological Aging, and Senile Dementia

Cited by 123 publications

References 31 publications

^99mTc-d,l-HMPAO and SPECT of the Brain in Normal Aging

^99mTc-d,l-HMPAO and SPECT of the Brain in Normal Aging

Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography.

Nefiracetam Improves the Impairment of Local Cerebral Blood Flow and Glucose Utilization after Chronic Focal Cerebral Ischemia in Rats

Contact Info

Product

Resources

About